Emicizumab is a medicine that helps prevent bleeding in people with hemophilia A, a condition where blood does not clot well. It is given as a shot under the skin, every one, two or four weeks. It works by doing the job of the missing clotting factor, helping the blood form clots.
Every report comes from a Lived member, sent anonymously.
Have you tried Hemlibra (Emicizumab) for Hemophilia A?
Emicizumab, sold as Hemlibra, is a prescription injection that prevents bleeding episodes in people with hemophilia A, an inherited condition in which the blood lacks enough working factor VIII, one of the proteins needed to form a clot. Without regular protection, people with more severe hemophilia A can bleed into joints and muscles with little or no injury, and repeated joint bleeds cause lasting damage. Hemlibra is approved for adults and children of any age, from newborns up, and it works whether or not the person has developed inhibitors. Inhibitors are antibodies the immune system sometimes makes against infused factor VIII, which make standard factor replacement much less effective. For people with inhibitors, emicizumab offers regular protection that factor VIII cannot. It is a preventive treatment taken on a schedule, not a treatment for a bleed that is already happening. Bleeds that break through still need factor VIII or a bypassing agent (a medicine that helps blood clot without using factor VIII).
Clotting works like a relay. When a blood vessel is injured, a series of proteins activate one another until a firm clot forms. In this chain, factor VIII acts as a connector: it holds two other clotting proteins, factor IX and factor X, close together so the next step can happen quickly. In hemophilia A, that connector is missing or does not work, so clots form too slowly. Emicizumab is a lab-made antibody with two different arms. One arm grabs activated factor IX and the other grabs factor X, bridging them the way factor VIII normally would. Because emicizumab is not factor VIII, inhibitors against factor VIII do not block it. It also stays in the body for weeks (about a month for half of it to clear), which is why it can be given far less often than factor VIII infusions.
Emicizumab is given as an injection under the skin, in the abdomen, thigh or upper outer arm, rather than into a vein. The dose is based on body weight. Treatment starts with a weekly loading dose for the first four weeks to build up levels, followed by a maintenance dose once a week, once every two weeks or once every four weeks. The schedule is chosen with the hemophilia team, often based on which one a person or family can keep up with most reliably. Tell the team if your weight changes, since the dose may need updating. After training, many people inject at home, or a caregiver gives the injection. Self-injection is not recommended for children under 7. Injection sites should be rotated, and the medicine is kept in the refrigerator; unopened vials can be out of the fridge for a total of no more than 7 days. When switching to emicizumab, regular preventive doses of a bypassing agent are stopped the day before the first injection. Preventive factor VIII can usually continue during the first week. If a dose is missed, give it as soon as possible and then return to the usual schedule, but never give two doses on the same day.
The most common side effects are reactions at the injection site (redness, tenderness, warmth or itching), headache and joint pain. In clinical trials, injection site reactions were mild to moderate, and most cleared up without treatment. Allergic reactions, including rash, hives and swelling of the face or lips, have been reported since approval. Rarely, the body makes antibodies against emicizumab that stop it from working well. Contact the hemophilia team promptly if bleeds become more frequent, since that can be the first sign the medicine is not protecting as it should.
The most important warning involves a bleeding treatment, not an everyday medicine. Activated prothrombin complex concentrate (aPCC, sold as FEIBA) is a bypassing agent some people with inhibitors use to treat bleeds. When large amounts of aPCC (on average more than 100 units per kilogram per day for a day or longer) were given to people on emicizumab, some developed serious blood clots or thrombotic microangiopathy, a condition in which small clots damage blood vessels and organs such as the kidneys. Because emicizumab lasts so long, this risk can continue for up to six months after the last dose. Before starting, agree with the hemophilia team exactly which product and dose to use for a breakthrough bleed, and check with them if more aPCC seems to be needed. Get medical help right away for signs of a clot or of thrombotic microangiopathy, particularly after receiving aPCC: chest pain or tightness, shortness of breath, coughing up blood, numbness in the face, trouble seeing, a painful, red or swollen arm or leg, confusion, yellowing of the skin or eyes, or passing much less urine. Emicizumab also makes some common clotting blood tests, including the aPTT and standard factor VIII and inhibitor tests, give falsely normal or misleading results. Tell any clinician who orders blood work or plans a procedure or surgery that you take emicizumab, so the right tests are used. This effect can also last up to six months after stopping. There is no information on use during pregnancy or breastfeeding. People who could become pregnant are advised to use contraception during treatment and to discuss pregnancy plans with their team.
Protection builds during the four weekly loading doses. In the main trials, people who switched from treating bleeds only when they happened to regular emicizumab had far fewer bleeds needing treatment, about 96 to 97 percent fewer in those without inhibitors and about 87 percent fewer in those with inhibitors, and many had no treated bleeds at all. Results vary, and emicizumab does not make blood clot normally, so injuries, surgery and dental work still need a plan with the hemophilia team. Emicizumab is a long-term treatment. Routine care includes regular visits with a hemophilia treatment center, keeping a record of any bleeds and what was used to treat them, and checking that the dose still matches body weight, especially in growing children. Many people find injections under the skin, given weekly or less often, easier to fit into daily life than frequent infusions into a vein.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Hemlibra (Emicizumab), what you've noticed, or ask the community a question.